FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017488575> ?p ?o ?g. }

• W2017488575 endingPage "1251" @default.
• W2017488575 startingPage "1242" @default.
• W2017488575 abstract "To estimate whether prenatal treatment with neuroprotective peptides prevents the developmental delay and the glial deficit in the Ts65Dn mouse model for Down syndrome and to explore the peptides' effects on achievement of normal development.Pregnant Ts65Dn females were randomly assigned to NAPVSIPQ+SALLRSIPA or control and were treated by investigators blinded to treatment and genotype on gestational days 8-12. Offspring were tested from postnatal day 5 to 21 for motor and sensory milestones with standardized tests by operators blinded to the pup's treatment and genotype. The pup's genotype was determined after completion of all tests. Activity-dependent neurotrophic factor, glial fibrillary acidic protein, and vasoactive intestinal peptide expression were determined using real-time polymerase chain reaction.Trisomic mice achieved milestones with a significant delay in four of five motor and sensory milestones. Trisomic mice that were prenatally exposed to NAPVSIPQ+SALLRSIPA achieved developmental milestones at the same time as the controls in three of four motor and one of four sensory milestones (P<.01). Euploid pups prenatally treated with NAPVSIPQ+SALLRSIPA achieved developmental milestones significantly earlier than the euploid pups prenatally treated with placebo. Activity-dependent neurotrophic factor expression was significantly downregulated in the Ts65Dn brains compared with the controls, prenatal treatment with NAPVSIPQ+ SALLRSIPA prevented the activity-dependent neurotrophic factor decrease in the Ts65Dn brains, and the expression was not different from the controls. The glial marker glial fibrillary acidic protein demonstrated the known glial deficit in the Ts65Dn mice, and treatment with NAPVSIPQ+ SALLRSIPA prevented its downregulation. Lastly, vasoactive intestinal peptide levels were increased in the trisomic brains, whereas treatment with NAPVSIPQ+SALLRSIPA did not prevent its upregulation.Prenatal treatment with NAPVSIPQ and SALLRSIPA prevented developmental delay and the glial deficit in Down syndrome. These findings highlight a possibility for the prevention of developmental sequelae in Down syndrome and suggest a potential intervention during pregnancy that may improve the outcome." @default.
• W2017488575 created "2016-06-24" @default.
• W2017488575 creator A5007592559 @default.
• W2017488575 creator A5007676851 @default.
• W2017488575 creator A5015262039 @default.
• W2017488575 creator A5023775553 @default.
• W2017488575 creator A5029087636 @default.
• W2017488575 creator A5051405380 @default.
• W2017488575 date "2008-12-01" @default.
• W2017488575 modified "2023-09-26" @default.
• W2017488575 title "Prevention of Developmental Delays in a Down Syndrome Mouse Model" @default.
• W2017488575 cites W1504564486 @default.
• W2017488575 cites W1505308024 @default.
• W2017488575 cites W1968318968 @default.
• W2017488575 cites W1977385486 @default.
• W2017488575 cites W1990414849 @default.
• W2017488575 cites W1996154142 @default.
• W2017488575 cites W2001501512 @default.
• W2017488575 cites W2006121336 @default.
• W2017488575 cites W2007920050 @default.
• W2017488575 cites W2022153638 @default.
• W2017488575 cites W2030645541 @default.
• W2017488575 cites W2039156594 @default.
• W2017488575 cites W2044715689 @default.
• W2017488575 cites W2046683337 @default.
• W2017488575 cites W2070039055 @default.
• W2017488575 cites W2084233122 @default.
• W2017488575 cites W2089405384 @default.
• W2017488575 cites W2099268443 @default.
• W2017488575 cites W2112663196 @default.
• W2017488575 cites W2112838942 @default.
• W2017488575 cites W2118000416 @default.
• W2017488575 cites W2121274568 @default.
• W2017488575 cites W2162843814 @default.
• W2017488575 cites W2171097783 @default.
• W2017488575 cites W2254607792 @default.
• W2017488575 doi "https://doi.org/10.1097/aog.0b013e31818c91dc" @default.
• W2017488575 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2687469" @default.
• W2017488575 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19037032" @default.
• W2017488575 hasPublicationYear "2008" @default.
• W2017488575 type Work @default.
• W2017488575 sameAs 2017488575 @default.
• W2017488575 citedByCount "43" @default.
• W2017488575 countsByYear W20174885752012 @default.
• W2017488575 countsByYear W20174885752013 @default.
• W2017488575 countsByYear W20174885752014 @default.
• W2017488575 countsByYear W20174885752015 @default.
• W2017488575 countsByYear W20174885752016 @default.
• W2017488575 countsByYear W20174885752017 @default.
• W2017488575 countsByYear W20174885752018 @default.
• W2017488575 countsByYear W20174885752019 @default.
• W2017488575 countsByYear W20174885752020 @default.
• W2017488575 countsByYear W20174885752022 @default.
• W2017488575 countsByYear W20174885752023 @default.
• W2017488575 crossrefType "journal-article" @default.
• W2017488575 hasAuthorship W2017488575A5007592559 @default.
• W2017488575 hasAuthorship W2017488575A5007676851 @default.
• W2017488575 hasAuthorship W2017488575A5015262039 @default.
• W2017488575 hasAuthorship W2017488575A5023775553 @default.
• W2017488575 hasAuthorship W2017488575A5029087636 @default.
• W2017488575 hasAuthorship W2017488575A5051405380 @default.
• W2017488575 hasBestOaLocation W20174885752 @default.
• W2017488575 hasConcept C112672928 @default.
• W2017488575 hasConcept C126322002 @default.
• W2017488575 hasConcept C134018914 @default.
• W2017488575 hasConcept C160539049 @default.
• W2017488575 hasConcept C170493617 @default.
• W2017488575 hasConcept C185856081 @default.
• W2017488575 hasConcept C204232928 @default.
• W2017488575 hasConcept C25498285 @default.
• W2017488575 hasConcept C2778790584 @default.
• W2017488575 hasConcept C2779234561 @default.
• W2017488575 hasConcept C2780495277 @default.
• W2017488575 hasConcept C54355233 @default.
• W2017488575 hasConcept C71924100 @default.
• W2017488575 hasConcept C86803240 @default.
• W2017488575 hasConcept C92020748 @default.
• W2017488575 hasConceptScore W2017488575C112672928 @default.
• W2017488575 hasConceptScore W2017488575C126322002 @default.
• W2017488575 hasConceptScore W2017488575C134018914 @default.
• W2017488575 hasConceptScore W2017488575C160539049 @default.
• W2017488575 hasConceptScore W2017488575C170493617 @default.
• W2017488575 hasConceptScore W2017488575C185856081 @default.
• W2017488575 hasConceptScore W2017488575C204232928 @default.
• W2017488575 hasConceptScore W2017488575C25498285 @default.
• W2017488575 hasConceptScore W2017488575C2778790584 @default.
• W2017488575 hasConceptScore W2017488575C2779234561 @default.
• W2017488575 hasConceptScore W2017488575C2780495277 @default.
• W2017488575 hasConceptScore W2017488575C54355233 @default.
• W2017488575 hasConceptScore W2017488575C71924100 @default.
• W2017488575 hasConceptScore W2017488575C86803240 @default.
• W2017488575 hasConceptScore W2017488575C92020748 @default.
• W2017488575 hasIssue "6" @default.
• W2017488575 hasLocation W20174885751 @default.
• W2017488575 hasLocation W20174885752 @default.
• W2017488575 hasLocation W20174885753 @default.
• W2017488575 hasLocation W20174885754 @default.
• W2017488575 hasOpenAccess W2017488575 @default.

• next